-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-520444-42-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-520445-23-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2025-523015-11-00
5
2026-03-18
Pericarditis
-
2023-509180-24-00
4
2026-02-12
vulvar cancer
-
2024-519798-20-00
4
2026-01-15
pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
-
2025-522026-13-00
4
2026-01-12
Obsessive compulsive disorder
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2025-521920-31-00
4
2025-11-21
Graves’ Disease
-
2024-519827-16-00
5
2025-09-30
Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2024-515640-22-00
6
2025-08-06
polypoidal choroidal vasculopathy
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-515214-41-00
5
2025-03-27
advanced pancreatic cancer